-
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.
-
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
-
Complaints pertaining to teeth are very common, and patients frequently utilize emergency departments (EDs) for their initial care. Most patients understand that definitive care must be provided by a dentist or oral surgeon, but either a lack of financial resources, inability to contact their dentist, severe pain, or acute trauma leads patients to EDs first.
-
-
A pacemaker is an electronic device that provides an electrical signal to stimulate the heart beat when the intrinsic pacemakers fail. The development and implementation of cardiac pacing and pacemaker generators has been well described and documented in many publications.
-
-
A program of resistive exercise and treadmill walking reduced the severity of restless legs syndrome symptoms.
-
People who have symptoms of allergic rhinitis report more sleep complaints, including daytime sleepiness, than do those without allergic rhinitis.
-
The FDA has approved a new antifungal agent for the prevention of Aspergillus and Candida infections in at-risk individuals. Posaconazole is an oral triazole, broad spectrum, antifungal chemically similar to itraconazole.
